EMA (EU)
GUIDANCE FINAL
Draft reflection paper on the clinical investigation of medicinal products for the treatment of systemic sclerosis
Published: 9/18/2026Detected: 9/18/2026
Summary preview
Provides a CHMP reflection framework for sponsors planning clinical development of medicinal products intended for systemic sclerosis, with particular emphasis on how to select patients, justify efficacy/treatment…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountimmunology
rare_diseases
dermatology
clinical
safety
labeling
quality
manufacturing
#systemic sclerosis
#scleroderma
#clinical development
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026